An update on Staphylococcus aureus infective endocarditis from the International Society of Antimicrobial Chemotherapy (ISAC)

Kordo Saeed (Corresponding Author), Abhijit Bal, Ian Gould, Michael Z. David, Matthew Dryden, Efthymia Giannitsioti, Karolin Hijazi, Jessica A. Meisner, Silvano Esposito, Francesco Scaglione, Pierre Tattevin, Andreas Voss

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Staphylococcus aureus remains one of the dominant pathogens in infective endocarditis (IE) causing 25% to 30% of all cases [1], [2] including healthcare-associated IE which comprises about 30% of IE [3]. Most IE involve the aortic or mitral valves, with tricuspid valve involvement accounting for fewer than 10% of cases, often in association with injection drug use [1], [4], [5]. Prosthetic valve IE (PVE) and IE related to cardiovascular implantable electronic devices accounts for approximately one-third of all cases and is most commonly caused by coagulase-negative staphylococci [1], [5].

S. aureus is equipped with microbial surface components recognizing adhesive matrix molecules (MSCRAMMS), which are well defined adhesion molecules on the bacterial surface, able to promote adherence to cardiac endothelial cells. S. aureus can multiply and persist within cardiac cells, further promoting vegetation growth via activation of cytokines and thrombotic pathways [6]. Moreover in S. aureus -PVE, surface biofilm formation complicates eradication of the infection. S. aureus has been identified as an independent predictor of poor outcome in IE [7], [8]. In this review an expert group from the International Society of Antimicrobial Chemotherapy (ISAC) will present recent data, evidence and personal experience on S. aureus IE.
Original languageEnglish
Pages (from-to)9-15
Number of pages7
JournalInternational Journal of Antimicrobial Agents
Volume53
Issue number1
Early online date19 Sep 2018
DOIs
Publication statusPublished - Jan 2019

Fingerprint

Endocarditis
Staphylococcus aureus
Drug Therapy
Tricuspid Valve
Coagulase
Biofilms
Aortic Valve
Mitral Valve
Staphylococcus
Adhesives
Endothelial Cells
Cytokines
Delivery of Health Care
Equipment and Supplies
Injections
Growth
Infection
Pharmaceutical Preparations

Keywords

  • MRSA
  • Staphylococcus aureus
  • infective endocarditis
  • PVL
  • prosthetic valve endocarditis
  • Panton–Valentine leukocidin
  • Infective endocarditis
  • Prosthetic valve endocarditis

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)

Cite this

An update on Staphylococcus aureus infective endocarditis from the International Society of Antimicrobial Chemotherapy (ISAC). / Saeed, Kordo (Corresponding Author); Bal, Abhijit; Gould, Ian; David, Michael Z.; Dryden, Matthew; Giannitsioti, Efthymia; Hijazi, Karolin; Meisner, Jessica A.; Esposito, Silvano; Scaglione, Francesco; Tattevin, Pierre; Voss, Andreas.

In: International Journal of Antimicrobial Agents, Vol. 53, No. 1, 01.2019, p. 9-15.

Research output: Contribution to journalArticle

Saeed, Kordo ; Bal, Abhijit ; Gould, Ian ; David, Michael Z. ; Dryden, Matthew ; Giannitsioti, Efthymia ; Hijazi, Karolin ; Meisner, Jessica A. ; Esposito, Silvano ; Scaglione, Francesco ; Tattevin, Pierre ; Voss, Andreas. / An update on Staphylococcus aureus infective endocarditis from the International Society of Antimicrobial Chemotherapy (ISAC). In: International Journal of Antimicrobial Agents. 2019 ; Vol. 53, No. 1. pp. 9-15.
@article{cc2c30bba369414f81cb78c292251d0d,
title = "An update on Staphylococcus aureus infective endocarditis from the International Society of Antimicrobial Chemotherapy (ISAC)",
abstract = "Staphylococcus aureus remains one of the dominant pathogens in infective endocarditis (IE) causing 25{\%} to 30{\%} of all cases [1], [2] including healthcare-associated IE which comprises about 30{\%} of IE [3]. Most IE involve the aortic or mitral valves, with tricuspid valve involvement accounting for fewer than 10{\%} of cases, often in association with injection drug use [1], [4], [5]. Prosthetic valve IE (PVE) and IE related to cardiovascular implantable electronic devices accounts for approximately one-third of all cases and is most commonly caused by coagulase-negative staphylococci [1], [5].S. aureus is equipped with microbial surface components recognizing adhesive matrix molecules (MSCRAMMS), which are well defined adhesion molecules on the bacterial surface, able to promote adherence to cardiac endothelial cells. S. aureus can multiply and persist within cardiac cells, further promoting vegetation growth via activation of cytokines and thrombotic pathways [6]. Moreover in S. aureus -PVE, surface biofilm formation complicates eradication of the infection. S. aureus has been identified as an independent predictor of poor outcome in IE [7], [8]. In this review an expert group from the International Society of Antimicrobial Chemotherapy (ISAC) will present recent data, evidence and personal experience on S. aureus IE.",
keywords = "MRSA, Staphylococcus aureus, infective endocarditis, PVL, prosthetic valve endocarditis, Panton–Valentine leukocidin, Infective endocarditis, Prosthetic valve endocarditis",
author = "Kordo Saeed and Abhijit Bal and Ian Gould and David, {Michael Z.} and Matthew Dryden and Efthymia Giannitsioti and Karolin Hijazi and Meisner, {Jessica A.} and Silvano Esposito and Francesco Scaglione and Pierre Tattevin and Andreas Voss",
note = "No funding",
year = "2019",
month = "1",
doi = "10.1016/j.ijantimicag.2018.09.014",
language = "English",
volume = "53",
pages = "9--15",
journal = "International Journal of Antimicrobial Agents",
issn = "0924-8579",
publisher = "Elsevier Science B. V.",
number = "1",

}

TY - JOUR

T1 - An update on Staphylococcus aureus infective endocarditis from the International Society of Antimicrobial Chemotherapy (ISAC)

AU - Saeed, Kordo

AU - Bal, Abhijit

AU - Gould, Ian

AU - David, Michael Z.

AU - Dryden, Matthew

AU - Giannitsioti, Efthymia

AU - Hijazi, Karolin

AU - Meisner, Jessica A.

AU - Esposito, Silvano

AU - Scaglione, Francesco

AU - Tattevin, Pierre

AU - Voss, Andreas

N1 - No funding

PY - 2019/1

Y1 - 2019/1

N2 - Staphylococcus aureus remains one of the dominant pathogens in infective endocarditis (IE) causing 25% to 30% of all cases [1], [2] including healthcare-associated IE which comprises about 30% of IE [3]. Most IE involve the aortic or mitral valves, with tricuspid valve involvement accounting for fewer than 10% of cases, often in association with injection drug use [1], [4], [5]. Prosthetic valve IE (PVE) and IE related to cardiovascular implantable electronic devices accounts for approximately one-third of all cases and is most commonly caused by coagulase-negative staphylococci [1], [5].S. aureus is equipped with microbial surface components recognizing adhesive matrix molecules (MSCRAMMS), which are well defined adhesion molecules on the bacterial surface, able to promote adherence to cardiac endothelial cells. S. aureus can multiply and persist within cardiac cells, further promoting vegetation growth via activation of cytokines and thrombotic pathways [6]. Moreover in S. aureus -PVE, surface biofilm formation complicates eradication of the infection. S. aureus has been identified as an independent predictor of poor outcome in IE [7], [8]. In this review an expert group from the International Society of Antimicrobial Chemotherapy (ISAC) will present recent data, evidence and personal experience on S. aureus IE.

AB - Staphylococcus aureus remains one of the dominant pathogens in infective endocarditis (IE) causing 25% to 30% of all cases [1], [2] including healthcare-associated IE which comprises about 30% of IE [3]. Most IE involve the aortic or mitral valves, with tricuspid valve involvement accounting for fewer than 10% of cases, often in association with injection drug use [1], [4], [5]. Prosthetic valve IE (PVE) and IE related to cardiovascular implantable electronic devices accounts for approximately one-third of all cases and is most commonly caused by coagulase-negative staphylococci [1], [5].S. aureus is equipped with microbial surface components recognizing adhesive matrix molecules (MSCRAMMS), which are well defined adhesion molecules on the bacterial surface, able to promote adherence to cardiac endothelial cells. S. aureus can multiply and persist within cardiac cells, further promoting vegetation growth via activation of cytokines and thrombotic pathways [6]. Moreover in S. aureus -PVE, surface biofilm formation complicates eradication of the infection. S. aureus has been identified as an independent predictor of poor outcome in IE [7], [8]. In this review an expert group from the International Society of Antimicrobial Chemotherapy (ISAC) will present recent data, evidence and personal experience on S. aureus IE.

KW - MRSA

KW - Staphylococcus aureus

KW - infective endocarditis

KW - PVL

KW - prosthetic valve endocarditis

KW - Panton–Valentine leukocidin

KW - Infective endocarditis

KW - Prosthetic valve endocarditis

UR - http://www.scopus.com/inward/record.url?scp=85057041879&partnerID=8YFLogxK

U2 - 10.1016/j.ijantimicag.2018.09.014

DO - 10.1016/j.ijantimicag.2018.09.014

M3 - Article

C2 - 30240836

VL - 53

SP - 9

EP - 15

JO - International Journal of Antimicrobial Agents

JF - International Journal of Antimicrobial Agents

SN - 0924-8579

IS - 1

ER -